[1] Pollheimer M J, Fickert P, Stieger B.Chronic cholestatic liver diseases:Clues from histopathology for pathogenesis. Mol Asp Med, 2014,37:35-56.
[2] Jansen P L, Ghallab A, Vartak N, et al.The ascending pathophysiology of cholestatic liver disease. Hepatology, 2017,65(2):722-738.
[3] You Z,Wang Q,Bian Z,et al.The immunopathology of liver granulomas in primary biliary cirrhosis.J Autoimmun,2012,39(3):216-221.
[4] Sun C, Xiao X,Yan L, et al. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase:Is alkaline phosphatase truly a surrogate marker J Autoimmun, 2019, 99: 33-38.
[5] Isayama H, Tazuma S, Kokudo N, et al.Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol, 2018,53(9):1006-1034.
[6] Lindor K D, Bowlus C L, Boyer J, et al.Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2019,69(1):394-419.
[7] EASL Clinical Practice Guidelines:The diagnosis and management of patients with primary biliary cholangitis. J Hepatol, 2017,67(1):145-172.
[8] Shi J, Wu C, Lin Y, et al.Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis:A Meta-analysis of randomized controlled trials. Am J Gastroenterol, 2006,101(7):1529-1538.
[9] Korula J.In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical response. Ann Intern Med, 2018,169(8):C45.
[10] Corpechot C, Chazouilleres O, Rousseau A, et al.A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med, 2018,378(23): 2171-2181.
[11] Nevens F, Andreone P, Mazzella G, et al.A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med, 2016,375(7):631-643.
[12] Kowdley K V, Luketic V, Chapman R, et al.A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018,67(5):1890-1902.
[13] Samur S, Klebanoff M, Banken R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology, 2017,65(3):920-928.
[14] Rautiainen H, Krkkinen P, Karvonen A, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:A three-year randomized trial. Hepatology, 2005,41(4):747-752.
[15] Hempfling W.Pharmacokinetics and pharmacodynamic action of budesonide in early-and late-stage primary biliary cirrhosis. Hepatology, 2003,38(1):196-202.
[16] Lleo A, Marzorati S, Anaya J, et al.Primary biliary cholangitis:a comprehensive overview. Hepatol Int, 2017,11(6):485-499.
[17] Eaton J E, Talwalkar J A, Lazaridis K N, et al.Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology, 2013,145(3):521-536.
[18] Tan L, Reilly C R, Steward-Harrison L C, et al. Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis. Gut, 2019,68(8):1533-1535.
[19] Hirschfield G M, Chazouillères O, Drenth J P, et al.Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis:A multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol, 2019,70(3):483-493.
[20] Ponsioen C Y, Arnelo U, Bergquist A, et al.No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis. Gastroenterology, 2018,155(3):752-759.
[21] 洪佳,吴晓宁,尤红. 胆汁淤积性肝病的规范化诊断. 实用肝脏病杂志, 2019,22(5):758-760. |
